Literature DB >> 1085681

The effect of Levamisole on peripheral blood lymphocyte subpopulations in patients with rheumatoid arthritis and ankylosing spondylitis.

M Rosenthal, U Trabert, W Müller.   

Abstract

Although Levamisole, an antihelmintic drug, has shown to have some modulatory effect on the immune response in clinical trials and experimental models, its mode of action remains obscure. In a group of fifteen patients with rheumatoid arthritis and ankylosing spondylitis receiving Levamisole on an intermittant regime, simultaneous determinations of the lymphocyte subpopulations were made prior to Levamisole administration and 3 months thereafter. No significant changes were observed either in the absolute or in the relative number of T- and B-cell populations, while a statistically significant reduction was found in the "null" cells. These findings suggest that the immune potentiating effect of Levamisole may at least partially be due to a maturation process of the "null" cells.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1085681      PMCID: PMC1541415     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  13 in total

1.  [Letter: Levamisole in the therapy of skin diseases].

Authors:  H Ippen; S A Qadripur
Journal:  Dtsch Med Wochenschr       Date:  1975-08-22       Impact factor: 0.628

2.  1958 Revision of diagnostic criteria for rheumatoid arthritis.

Authors:  M W ROPES; G A BENNETT; S COBB; R JACOX; R A JESSAR
Journal:  Bull Rheum Dis       Date:  1958-12

3.  Enhanced binding of neuraminidase-treated sheep erythrocytes to human T lymphocytes.

Authors:  M S Weiner; C Bianco; V Nussenzweig
Journal:  Blood       Date:  1973-12       Impact factor: 22.113

4.  Identification by peroxidase staining of monocytes in surface immunofluorescence tests.

Authors:  J L Preud'homme; G Flandrin
Journal:  J Immunol       Date:  1974-11       Impact factor: 5.422

5.  Subpopulations of human peripheral blood lymphocytes distinguished by combined rosette formation and membrane immunofluorescence.

Authors:  M Papamichail; E J Holborow; H I Keith; H L Currey
Journal:  Lancet       Date:  1972-07-08       Impact factor: 79.321

6.  Drug-induced restoration of cutaneous delayed hypersensitivity in anergic patients with cancer.

Authors:  D Tripodi; L C Parks; J Brugmans
Journal:  N Engl J Med       Date:  1973-08-16       Impact factor: 91.245

7.  The treatment of systemic lupus erythematosus (SLE) with the T-cell immunostimulant drug levamisole: A case report.

Authors:  B L Gordon; J P Keenan
Journal:  Ann Allergy       Date:  1975-12

8.  Lymphocyte subpopulations in normals and patients with rheumatoid arthritis and ankylosing spondylitis.

Authors:  M Rosenthal; W Muller
Journal:  J Rheumatol       Date:  1975-12       Impact factor: 4.666

9.  Immunostimulant therapy with levamisole for rheumatoid arthritis.

Authors:  E C Huskisson; J Scott; H W Balme; P A Dieppe; J Trapnell; D A Willoughby
Journal:  Lancet       Date:  1976-02-21       Impact factor: 79.321

10.  Thymosin-induced reduction of "null cells" in peripheral-blood lymphocytes of patients with systemic lupus erythematosus.

Authors:  M A Scheinberg; E S Cathcart; A L Goldstein
Journal:  Lancet       Date:  1975-02-22       Impact factor: 79.321

View more
  8 in total

1.  Levamisole monotherapy for oral lichen planus.

Authors:  Tai Hyok Won; Se Young Park; Bo Suk Kim; Phil Seung Seo; Seok Don Park
Journal:  Ann Dermatol       Date:  2009-08-31       Impact factor: 1.444

2.  Effect of levamisole on autologous rosette-forming cells in nude mice.

Authors:  J Van Wauwe; G Van Nijen
Journal:  Clin Exp Immunol       Date:  1977-12       Impact factor: 4.330

3.  Thymopoietin and levamisole in chronic granulomatous inflammation.

Authors:  P A Thrower; A D Sedgwick; E R Smith; D A Willoughby; E C Huskisson
Journal:  Ann Rheum Dis       Date:  1983-02       Impact factor: 19.103

4.  Immunological recovery after measles.

Authors:  A Wesley; H M Coovadia; L Henderson
Journal:  Clin Exp Immunol       Date:  1978-06       Impact factor: 4.330

5.  Levamisole-induced lichenoid eruptions.

Authors:  J D Kirby; M Black; D McGibbon
Journal:  J R Soc Med       Date:  1980-03       Impact factor: 18.000

6.  Efficacy and safety of Levamisole treatment in clinical presentations of non-hospitalized patients with COVID-19: a double-blind, randomized, controlled trial.

Authors:  Amirreza Roostaei Firozabad; Zohreh Akhoundi Meybodi; Seyed Ruhollah Mousavinasab; Adeleh Sahebnasagh; Mohsen Gholinataj Jelodar; Iman Karimzadeh; Solomon Habtemariam; Fatemeh Saghafi
Journal:  BMC Infect Dis       Date:  2021-03-24       Impact factor: 3.090

Review 7.  Anti-helminthic drugs in recurrent apthous stomatitis: A short review.

Authors:  Shilpa Sharma; Fareedi Mukram Ali; Kedar Saraf; Anupama Mudhol
Journal:  J Pharm Bioallied Sci       Date:  2014-04

Review 8.  Pharmacological treatments of COVID-19.

Authors:  Adeleh Sahebnasagh; Razieh Avan; Fatemeh Saghafi; Mojataba Mojtahedzadeh; Afsaneh Sadremomtaz; Omid Arasteh; Asal Tanzifi; Fatemeh Faramarzi; Reza Negarandeh; Mohammadreza Safdari; Masoud Khataminia; Hassan Rezai Ghaleno; Solomon Habtemariam; Amirhosein Khoshi
Journal:  Pharmacol Rep       Date:  2020-08-20       Impact factor: 3.919

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.